Sympathomimetics should be used with caution in patients with glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, prostatic hypertrophy or bladder neck obstruction, cardiovascular disease, increased intraocular pressure or diabetes mellitus.
Sympathomimetics should be used with caution in patients receiving digitalis.
Sympathomimetics may cause central nervous system (CNS) stimulation, excitability, convulsions and/or cardiovascular collapse with accompanying hypotension.
In patients 60 years of age or older, sympathomimetics are also more likely to cause adverse reactions such as confusion, hallucination, convulsions, CNS depression and death. Consequently, caution should be exercised when administering a repeat-action formulation to elderly patients.
Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine; for ER tablet, initial dose of 1 tablet every other day is recommended. For repetab, initial dose of one tablet daily is recommended.
Patients who have a history of difficulty in swallowing tablets or who have known upper GI narrowing or abnormal oesophageal peristalsis should not use Clarinase tablets.
Drug Abuse and Dependence: There are no data available to indicate that abuse or dependency occurs with loratadine.
Pseudoephedrine sulfate, like other CNS stimulants, has been abused. At high doses, subjects commonly experience an elevation of mood, decreased appetite and a sense of increased physical energy, mental capacity and alertness. Anxiety, irritability and loquacity also have been experienced. With continued use, tolerance develops; the use increases the doses and ultimately toxicity occurs. Depression may follow rapid withdrawal.
Use in Children: Safety and efficacy of CLARINASE REPETABS/Clarinase ER tab in children younger than 12 years of age have not yet been established.